Protalex (OTCMKTS:PRTX) and Iqvia (NYSE:IQV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.
This table compares Protalex and Iqvia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Protalex has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Comparatively, Iqvia has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
Insider and Institutional Ownership
0.2% of Protalex shares are held by institutional investors. Comparatively, 91.0% of Iqvia shares are held by institutional investors. 80.0% of Protalex shares are held by insiders. Comparatively, 6.0% of Iqvia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Protalex and Iqvia’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Iqvia||$10.41 million||2,522.64||$259.00 million||$5.12||26.00|
Iqvia has higher revenue and earnings than Protalex.
This is a summary of recent ratings and price targets for Protalex and Iqvia, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Iqvia has a consensus price target of $147.20, indicating a potential upside of 10.56%. Given Iqvia’s higher possible upside, analysts plainly believe Iqvia is more favorable than Protalex.
Iqvia beats Protalex on 10 of the 11 factors compared between the two stocks.
Protalex Company Profile
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
Iqvia Company Profile
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Protalex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalex and related companies with MarketBeat.com's FREE daily email newsletter.